Showing 3041-3050 of 6035 results for "".
- TearClear Appoints Robert J. Dempsey Chief Executive Officerhttps://modernod.com/news/tearclear-appoints-robert-j-dempsey-chief-executive-officer/2477596/TearClear announced the appointment of Robert J. Dempsey as Chief Executive Officer. TearClear is the only pharmaceutical company to administer preservative free eye drops to the ocular surface, that are preserved safely prior to dosing, according to a company news release. <
- Leo Lens Pharma Appoints Dan Myers CEOhttps://modernod.com/news/leo-lens-pharma-appoints-dan-myers-ceo/2477589/Leo Lens Pharma has announced the appointment of Dan Myers as Chief Executive Officer. Prior to joining Leo Lens, Mr. Myers was the co-founder and Chief Executive Officer of Alimera Sciences, where he continues to serve as chairman of the Board of Directors. Before founding Alimera, Mr. Myers was
- FDA Quickly Authorizes Its 2nd Blood Filtering Device for COVID-19https://modernod.com/news/fda-quickly-authorizes-its-2nd-blood-filtering-device-for-covid-19/2477585/Shortly after granting an emergency authorization to Terumo BCT’s blood filtering device for COVID-19, the FDA did the same for CytoSorbents’ system, according to a FierceBiotech
- New Peer-Reviewed Paper Offers Advice to Contact Lens Practitioners During COVID-19 Pandemichttps://modernod.com/news/new-peer-reviewed-paper-offers-advice-to-contact-lens-practitioners-during-covid-19-pandemic/2477569/A new peer-reviewed paper from five prominent ocular scientists aims to help eye care practitioners (ECPs) instruct and reassure contact lens wearers during the global COVID-19 pandemic. Published in Contact Lens & Anterior Eye,
- Contact Lens Institute Shares New CDC Guidance for Contact Lens Wear and COVID-19https://modernod.com/news/contact-lens-institute-shares-new-cdc-guidance-for-contact-lens-wear-and-covid-19/2477563/The Contact Lens Institute is sharing new guidance issued this week by the U.S. Centers for Disease Control and Prevention (CDC) regarding contact lens wear and care amid the COVID-19 pandemic. The direction,
- Pfizer Aims to Start Clinical Testing of Lead Compound Against SARS-CoV-2 in Third Quarterhttps://modernod.com/news/pfizer-aims-to-start-clinical-testing-of-lead-compound-against-sars-cov-2-in-third-quarter/2477560/In an update on its efforts to combat COVID-19, Pfizer said results of initial screening assays have led it to zero in on a lead protease inhibitor with antiviral activity against SARS-CoV-2 based on preliminary data. The company stated that it will now perform preclinical testing on the compound
- LambdaVision Wins NASA Award to Further Advance Development of an Artificial Retinahttps://modernod.com/news/lambdavision-wins-nasa-award-to-further-advance-development-of-an-artificial-retina/2477556/LambdaVision, along with implementation partner, Space Tango, has been selected by NASA for an award of $5 million. This new funding will support LambdaVision’s development of the first protein-based artificial retina to restore meaningful vision for patients who are blind or have lost significan
- GlaxoSmithKline Takes $250 Million Stake in Vir as Companies Pair Up to Develop Coronavirus Treatmentshttps://modernod.com/news/glaxosmithkline-takes-250-million-stake-in-vir-as-companies-pair-up-to-develop-coronavirus-treatments/2477536/GlaxoSmithKline and Vir Biotechnology announced that they have agreed to enter into a collaboration to develop anti-viral antibodies for coronaviruses, including SARS-CoV-2. In addition, to gain access to Vir’s monoclonal antibody technology, GlaxoSmithKline said it will also make an equity
- FDA Issues New Policy for Remote Ophthalmic Assessment and Monitoring Devices During COVID-19https://modernod.com/news/fda-issues-new-policy-for-remote-ophthalmic-assessment-and-monitoring-devices-during-covid-19/2477535/The FDA issued immediate guidance to help expand the capability of remote ophthalmic assessment and monitoring devices. These devices include visual acuity charts, visual field devices, general use ophthalmic cameras, and tonometers. This guidance is intended to help facilitate patient c
- Iveric bio Announces Fast Track Designation From FDA for Zimura for Treatment of Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/iveric-bio-announces-fast-track-designation-from-fda-for-zimura-for-treatment-of-geographic-atrophy-secondary-to-dry-amd/2477528/Iveric bio announced that the FDA has granted Fast Track designation to Zimura (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Currently, there is no FDA or EMA appro